Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 9:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Metastatic Castrate-sensitive Prostate Cancer Clear all
Completed Phase 2 Interventional Results available

Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations

NCT03413995
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
Rucaparib
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Jun 25, 2026, 9:45 PM EDT
Recruiting Phase 1 Interventional

Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer

NCT05997615
View directory record Official record
Conditions
Hormone-refractory Prostate Cancer
Interventions
VIR-5500, ARSI
Drug · Combination Product
Lead sponsor
Vir Biotechnology, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
437 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
Palo Alto, California • Houston, Texas • Fairfax, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jun 25, 2026, 9:45 PM EDT
Active, not recruiting Phase 4 Interventional

PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer

NCT06479187
View directory record Official record
Conditions
Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Interventions
18F-rhPSMA-7.3, PET/CT
Drug · Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Jun 25, 2026, 9:45 PM EDT
Recruiting Phase 1 Interventional

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

NCT05818683
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Neoplasms, Metastatic Hormone-sensitive Prostate Cancer
Interventions
Pasritamig, Cetrelimab, Cabazitaxel, Docetaxel, Apalutamide, Enzalutamide, Darolutamide, Abiraterone acetate plus prednisone (AAP), Lutetium Lu-177 vipivotide tetraxetan, JNJ-101556143
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
Sarasota, Florida • Grand Rapids, Michigan • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 25, 2026, 9:45 PM EDT
Completed No phase listed Observational Results available

A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

NCT06072196
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Novel hormonal therapy
Drug
Lead sponsor
Pfizer
Industry
Eligibility
65 Years and older · Male only
Enrollment
3,017 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Jun 25, 2026, 9:45 PM EDT
Active, not recruiting Phase 3 Interventional

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

NCT06120491
View directory record Official record
Conditions
Metastatic Castration-Sensitive Prostate Cancer
Interventions
Saruparib, Placebo, Abiraterone Acetate, Darolutamide, Enzalutamide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Male only
Enrollment
1,889 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
71
States / cities
Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jun 25, 2026, 9:45 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

NCT04821622
View directory record Official record
Conditions
Prostate Cancer
Interventions
talazoparib plus enzalutamide, Placebo plus enzalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
45
States / cities
Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Jun 25, 2026, 9:45 PM EDT
Completed Phase 2 Interventional Results available

CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone

NCT03934840
View directory record Official record
Conditions
Prostate Cancer
Interventions
Cabazitaxel, Carboplatin, Abiraterone, Prednisone
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Male only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
8
States / cities
Phoenix, Arizona • Chicago, Illinois • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jun 25, 2026, 9:45 PM EDT
Completed Phase 4 Interventional

Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis

NCT00035997
View directory record Official record
Conditions
Prostate Cancer
Interventions
Zometa
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
56
States / cities
Birmingham, Alabama • Anchorage, Alaska • Anaheim, California + 50 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2009 · Synced Jun 25, 2026, 9:45 PM EDT
Completed Phase 2 Interventional

Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer

NCT06312670
View directory record Official record
Conditions
Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Prostate Cancer, Prostate Adenocarcinoma
Interventions
EPI-7386, Enzalutamide, Androgen Deprivation Therapy (ADT)
Drug
Lead sponsor
Pedro Barata, MD, MSc
Other
Eligibility
19 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Jun 25, 2026, 9:45 PM EDT
Recruiting Phase 2 Interventional

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

NCT04734730
View directory record Official record
Conditions
Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Abiraterone Acetate, Bicalutamide, Degarelix, Goserelin Acetate, Leuprolide Acetate, Prednisone, Questionnaire Administration, Talazoparib
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Jun 25, 2026, 9:45 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Toxicity & Pharmacokinetics of 2 & 3-weekly Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

NCT03343977
View directory record Official record
Conditions
Metastatic Hormone-Sensitive Prostate Cancer
Interventions
docetaxel 50mg/m2, docetaxel 75mg/m2
Drug
Lead sponsor
Peng Wang, MD PhD
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Jun 25, 2026, 9:45 PM EDT
Completed No phase listed Observational Results available

A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces

NCT06151418
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Novel hormonal therapy
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
2,313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Jun 25, 2026, 9:45 PM EDT
Recruiting Phase 2 Interventional

FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial

NCT06244004
View directory record Official record
Conditions
Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Antiandrogen Therapy, Bone Scan, Computed Tomography, Cytotoxic Chemotherapy, FDG-Positron Emission Tomography, Radiation Therapy
Drug · Procedure · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
6
States / cities
Chicago, Illinois • DeKalb, Illinois • Geneva, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Jun 25, 2026, 9:45 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer

NCT05067140
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
ARV-766 Part A&B, ARV-766 + Abiraterone Part C&D
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
23
States / cities
Duarte, California • Fresno, California • La Jolla, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jun 25, 2026, 9:45 PM EDT
Recruiting Phase 3 Interventional

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

NCT07028853
View directory record Official record
Conditions
Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
Interventions
Mevrometostat, Placebo, Enzalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
122
States / cities
Huntsville, Alabama • Chandler, Arizona • Gilbert, Arizona + 87 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jun 25, 2026, 9:45 PM EDT
Active, not recruiting Phase 1 Interventional

Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer

NCT06555796
View directory record Official record
Conditions
Prostate Cancer, High-risk Biochemical Recurrence, High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer, Non-metastatic Castration-sensitive Prostate Cancer
Interventions
Xaluritamig
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
8
States / cities
Minneapolis, Minnesota • New York, New York • Chapel Hill, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Jun 25, 2026, 9:45 PM EDT
Terminated Phase 1 Interventional

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

NCT05733351
View directory record Official record
Conditions
Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Abiraterone, Biospecimen Collection, Bone Scan, Computed Tomography, Docetaxel, Enzalutamide, FDG-Positron Emission Tomography, Magnetic Resonance Imaging, PSMA PET Scan, Vudalimab
Drug · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Jun 25, 2026, 9:45 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

NCT05288166
View directory record Official record
Conditions
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
Interventions
Abemaciclib, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
925 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
63
States / cities
Prescott, Arizona • Prescott Valley, Arizona • Tucson, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Jun 25, 2026, 9:45 PM EDT
Completed Phase 1 Interventional

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

NCT04477512
View directory record Official record
Conditions
Metastatic Hormone Refractory Prostate Cancer
Interventions
Cabozantinib, Nivolumab, Abiraterone acetate, Prednisone, Peripheral blood collection
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Jun 25, 2026, 9:45 PM EDT
Completed Phase 2 Interventional Results available

LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer

NCT02058706
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
enzalutamide, bicalutamide, orchiectomy, leuprolide acetate, goserelin acetate, laboratory biomarker analysis
Drug · Procedure · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
4
States / cities
Birmingham, Alabama • Detroit, Michigan • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Jun 25, 2026, 9:45 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

NCT00544830
View directory record Official record
Conditions
PSA Level Greater Than Two, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Bicalutamide, Goserelin Acetate, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Leuprolide Acetate
Drug · Radiation · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2027
U.S. locations
2
States / cities
Duarte, California • South Pasadena, California
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jun 25, 2026, 9:45 PM EDT
Active, not recruiting Phase 3 Interventional

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

NCT04720157
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
1,140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
70
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jun 25, 2026, 9:45 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer

NCT02059213
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ibrance, Bicalutamide, Zoladex, Lupron Depot
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
8
States / cities
Duarte, California • Chicago, Illinois • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Jun 25, 2026, 9:45 PM EDT